NewsHealth / October 29, 2020

U.S. Government To Purchase Eli Lilly COVID-19 Antibody Drug Pending FDA Approval

Article origination IPBS-RJC
Eli Lilly's Corporate Headquarters in Indianapolis. The company has agreed to supply an initial 300,000 doses of its COVID-19 antibody drug to the U.S. government to be distributed across the country.  - Lauren Chapman/IPB News

Eli Lilly's Corporate Headquarters in Indianapolis. The company has agreed to supply an initial 300,000 doses of its COVID-19 antibody drug to the U.S. government to be distributed across the country.

Lauren Chapman/IPB News

The U.S. government has agreed to purchase 300,000 doses of Eli Lilly’s COVID-19 antibody treatment. It plans to pay $375 million for the vials of the drug.

An additional 650,000 doses could be purchased from the Indianapolis-based pharmaceutical company through June 2021.

Patients who receive the medication distributed by the U.S. government will not have any out-of-pocket costs for the drug, but may have to pay a fee for its administration.

Peer reviewed data published in the New England Journal of Medicine showed the drug may have “potential” in treating mild to moderate COVID-19 patients.

The Food and Drug Administration has yet to approve an emergency use authorization application from Lilly that was submitted earlier this month.

Lilly said it plans to produce up to 1 million doses by the end of the year.

Contact reporter Samantha at shorton@wfyi.org or follow her on Twitter at @SamHorton5.

At WFYI, our goal is to cover stories that matter to you. Our reporting is rooted in facts. It considers all perspectives and is available to everyone. We don't have paywalls, but we do need support. So if unbiased, trusted journalism is important to you, please join us. Donate now.

 

 

Related News

More Than 10 Percent Of Hoosiers Have Been Infected With COVID-19, Says Fairbanks Study
Hospital Diversions Don't Mean Patients Can't Seek Emergency Care
Allen County Imposes Restrictions Amid Growth In COVID Cases